SURGERY PARTNERS ($NASDAQ:SGRY) announced their earnings results for the second quarter of FY2023 on June 30, 2023. Total revenue increased by 8.5% to USD 667.6 million when compared to the same quarter of the previous year, and net income soared to USD 18.9 million, a significant reversal from the -18.4 million reported in the same period the year prior.
The stock opened at $37.6 and closed at $36.9, which marked a decrease of 4.4% from its previous closing price of 38.6. This indicates that the company has been able to effectively manage its operations and expenses, allowing them to maintain a strong financial position even in the face of a decline in sales. Although the stock price decreased as a result of the report, the company appears to be in a strong financial position for future growth and success. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Surgery Partners. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Surgery Partners. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Surgery Partners. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Surgery Partners are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Surgery Partners Stock Fair Value Calculator
As GoodWhale, we have conducted an analysis of SURGERY PARTNERS‘s fundamental metrics. We have determined that the fair value of SURGERY PARTNERS share is around $31.1 through our proprietary Valuation Line. Right now, SURGERY PARTNERS stock is traded at $36.9, meaning that it is a fair price but is overvalued by 18.7%. More…
Risk Rating Analysis
Star Chart Analysis
It is one of the largest surgical providers in the country and faces competition from other providers such as Cross Country Healthcare Inc, Genesis Healthcare Inc, and PT Mitra Keluarga Karyasehat Tbk. All of these companies provide quality healthcare services for their respective markets and have an established presence in the surgical services sector.
– Cross Country Healthcare Inc ($NASDAQ:CCRN)
Cross Country Healthcare Inc is a leading provider of healthcare staffing and workforce solutions. With a market cap of 1.04 billion as of 2023, the company is well-positioned to capitalize on the growing demand for its services. Cross Country Healthcare Inc’s Return on Equity of 44.54% reflects the fact that the company is generating strong returns for its shareholders. The company offers a variety of solutions, from short-term staffing to long-term strategic workforce planning, that can help healthcare facilities optimize their staffing and operations. With its highly experienced team and industry-leading solutions, Cross Country Healthcare Inc is well positioned to continue to be a leader in the healthcare staffing space.
– Genesis Healthcare Inc ($OTCPK:GENN)
Genesis Healthcare Inc is a leading national provider of post-acute care services, offering long-term care and rehabilitation services at more than 500 skilled nursing centers and assisted/senior living communities in 34 states. As of 2023, the company has a market cap of 1.97M, indicating its relative small size compared to other healthcare providers. Despite its small size, Genesis Healthcare Inc has performed relatively well, evidenced by its Return on Equity of -2.17%. This metric is a measure of how much profit a company is able to generate from its shareholders’ investments, and a negative number indicates that the company is not generating a sufficient return on equity.
– PT Mitra Keluarga Karyasehat Tbk ($IDX:MIKA)
PT Mitra Keluarga Karyasehat Tbk is a leading provider of health and wellness services in Indonesia. The company has a current market cap of 42.7T, making it one of the largest companies in the country. PT Mitra Keluarga Karyasehat Tbk has achieved a remarkable 18.07% Return on Equity, which indicates that the company is able to generate a significant return on its shareholders’ equity. This demonstrates the company’s ability to efficiently manage its resources and generate a healthy return for its shareholders.
SURGERY PARTNERS recently reported their earnings results for the second quarter of FY2023 with total revenue up 8.5% year-over-year to USD 667.6 million and net income of USD 18.9 million, a notable improvement from the -18.4 million reported in the same quarter last year. Despite this, the stock price still dropped the same day, likely due to investors expecting a larger profit increase than the 8.5% growth in total revenue. Nevertheless, SURGERY PARTNERS is making great progress and looks to be a promising investment opportunity going forward.